

Certificate of Analysis

Arg, active

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-521, 14-521-K, 14-521M

Parent Lot # 25777U

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialling runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialling run.

Product Description: N-terminal 6His-tagged recombinant human Arg residues 38–end. This is expressed by baculovirus in Sf21 insect cells. Purified using Ni²⁺/NTA-agarose. Purity 32.7% by SDS-PAGE and Coomassie staining. MW = 121.9kDa.

Specific Activity (Parent lot# 25777U): 1948U/mg, where one unit of Arg, active activity is defined as 1nmol phosphate incorporated into 50μM Abltide (EAIYAAPFAKKK) per minute at 30°C with a final ATP concentration of 100μM.

Formulation: 0.775mg/ml of enzyme in 50mM Tris/HCl pH7.5, 150mM NaCl, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1mM EGTA, 0.1% 2-mercaptoethanol, 0.03% Brij-35. Frozen solution.


Storage and Stability: On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 1 year from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

Handling Recommendations: Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled micro-centrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY
NOT FOR USE IN HUMANS OR ANIMALS**

Quality Control Testing

Kinase Assay: 2.12–5.84ng of this lot of enzyme phosphorylated 50μM Abltide in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



MS Tryptic Fingerprint: Confirmed identity as Arg with the translated sequence listed on page three.



Certificate of Analysis

Kinase Assay Protocol

Stock Solutions:

1. **5 x Reaction Buffer:** 40mM MOPS/NaOH pH7.0, 1mM EDTA.
2. **Abltide (EAIYAAPFAKKK):** Use at a final assay concentration of 50 μ M. Prepare a 500 μ M stock and add 2.5 μ l of stock per assay point.
3. **Arg, active:** Dilute with 20mM MOPS/NaOH pH7.0, 1mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 2.12–5.84ng per assay point.
4. **[γ -³³P]ATP:** 2.5 x magnesium acetate/[γ -³³P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [γ -³³P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)

Assay Procedure (96 well plate format):

1. Add 5 μ l of 5 x reaction buffer.
2. Add 2.5 μ l of **(EAIYAAPFAKKK)**.
3. Add **2.5 μ l (2.12–5.84ng) Arg, active**.
4. Add 5 μ l of dH₂O.
5. Add 10 μ l of diluted [γ -³³P]ATP mixture.
6. Incubate for 10 minutes at 30°C.
7. Stop the reaction by adding 5 μ l of 3% phosphoric acid.
8. Transfer a 10 μ l aliquot onto the appropriate area of a **P30 Filtermat**.
9. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
10. Wash the filtermat once for 2 minutes with methanol.
11. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
12. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1 μ l of 30% phosphoric acid.

Certificate of Analysis

Arg Sequence Information

<u>Protein</u>	human Arg (38–end)
<u>Tags</u>	N-terminal 6His
<u>Native sequence</u>	E10 of the recombinant protein is equivalent to E28 of human Arg
<u>Accession number</u>	GenBank NM_005158

Recombinant Arg amino acid sequence:

1	MHHHHHHEFE	ALHRPYGCDV	EPQALNEAIR	WSSKENLLGA	TESDPNLFVA	LYDFVASGDN
61	TLSITKGEKL	RVLGYNQNGE	WSEVRSKNGQ	GWVPSNYITP	VNSLEKHSWY	HGPVSRSAAE
121	YLLSSLINGS	FLVRESESSP	GQLSISLRYE	GRVYHYRINT	TADGKVYVTA	ESRFSTLAEL
181	VHHHSTVADG	LVTTLHYAP	KCNKPTVYGV	SPIHDKWEME	RTDITMKHKL	GGGQYGEVYV
241	GVWKYSLTV	AVKTLKEDTM	EVEEFLKEAA	VMKEIKHPNL	VQLLGVCLE	PPFYIVTEYM
301	PYGNLLDYLR	ECNREEVTAV	VLLYMATQIS	SAMEYLEKKN	FIHRDLAARN	CLVGENHVVK
361	VADFGLSRLM	TGDTYTAHAG	AKFPIKWTP	ESLAYNTFSI	KSDVWAFGLV	LWEIATYGMS
421	PYPGIDLSQV	YDLLEKGYRM	EQPEGCPKV	YELMRACWKW	SPADRPSFAE	THQAFETMFH
481	DSSISEEVAE	ELGRAASSSS	VVPYLPRLPI	LPSKTRTLKK	QVENKENIEG	AQDATENSAS
541	SLAPGFIRGA	QASSGSPALP	RKQRDKSPSS	LLEDAKETCF	TRDRKGGFFS	SFMKKRNAPT
601	PPKRSSSFRE	MENQPHKKYE	LTGNFSSVAS	LQHADGFSFT	PAQQEANLVP	PKCYGGSFAQ
661	RNLCNDDGGG	GGSGTAGGG	WSGITGFFTP	RLIKKTLGLR	AGKPTASDDT	SKFPFRSNST
721	SSMSSGLPEQ	DRMAMTLPRN	CQRSKLQLER	TVSTSSQPEE	NVDRANDMLP	KKSEESAAPS
781	RERP KAKLLP	RGATALPLRT	PSGDLAITEK	DPPGVGVAGV	AAAPKGKEKN	GGARLGMAGV
841	PEDGEQPGWP	SPAKAAPVLP	TTHNHKVPVL	ISPTLKHTPA	DVQLIGTDSQ	GNKFKLLSEH
901	QVTSSGDKDR	PRRVKPKCAP	PPPPVMRLLO	HPSICSDPTE	EPTALTAGQS	TSETQEGGKK
961	AALGAVPISG	KAGRPVMPPP	QVPLPTSSIS	PAKMANGTAG	TKVALRKTKQ	AAEKISADKI
1021	SKEALLECAD	LLSSALTEPV	PNSQLVDTGH	QLLDYCSGYV	DCIPQTRNKF	AFREAVSKLE
1081	LSIQELQVSS	AAAGVPGTNP	VLNNLLSCVQ	EISDVVQR		

Recombinant Arg nucleotide sequence:

1	atgcatcatc	accatcacca	tgaattcgaa	gctttgcatc	gtccctatgg	ttgtgatgtt
61	gaaccccagg	cactaaatga	ggctatcagg	tggagctcca	aggagaactt	gctcggagcc
121	actgagagtg	accctaactc	cttcgttgca	ctttatgatt	ttgtagcaag	tggtgataac
181	acactcagca	tcactaaagg	tgaaaagcta	cgagtccttg	gttacaacca	gaatggtgag
241	tggagtgaag	ttcgctctaa	gaatgggcag	ggctgggtgc	caagcaacta	catcacccca
301	gtgaacagcc	tggaaaaaca	ctcctggtag	catggacctg	tgtcacgcag	tgcagctgag
361	tatctgctca	gcagtctaata	caatggcagc	ttcctgggtgc	gagaaagtga	gagtagccct
421	gggcagctgt	ccatctcgct	caggtacgag	ggacgtgtat	atcactacag	gatcaatacc
481	actgcagatg	gcaaggtgta	tgtgactgct	gagagccgct	tcagcacctt	ggcagagctt
541	gtacaccatc	actccacagt	ggctgatggg	ctgggtgacaa	cattacacta	cccagcacc
601	aagtgtataa	agcctacagt	ctatggtgtg	tccccatcc	acgacaaatg	ggaaatggag
661	cgaacagata	ttacatgaa	gcacaaactt	gggggcggtc	agtatggaga	ggtttacgtt
721	ggcgtctgga	agaaatacag	ccttacagtt	gctgtgaaaa	cattgaagga	agataccatg
781	gaggtagaag	aattcctgaa	agaagctgca	gtaatgaagg	aaatcaagca	tcctaactctg
841	gtacaacttt	taggtgtgtg	tactttggag	ccaccatttt	acattgtgac	tgaatacatg
901	ccatacgga	atttgctgga	ttacctccga	gaatgcaacc	gagaagaggt	gactgcagtt
961	gtgctgctct	acatggccac	tcagatttct	tctgcaatgg	agtacttaga	gaagaagaat
1021	ttcatccata	gagatcttgc	agctcgtaac	tgcctagtgg	gagaaaacca	tgtggtaaaa
1081	gtggctgact	ttggcttaag	tagattgatg	actggagaca	cttatactgc	tcatgctgga
1141	gccaaatttc	ctattaagtg	gacagcacca	gagagtcttg	cctacaatac	cttctcaatt
1201	aaatctgacg	tctgggcttt	tggggtattg	ttgtgggaaa	ttgctaccta	tggaatgtca
1261	ccatatccag	gtattgacct	gtctcaggct	tatgacctac	tagaaaaagg	atatcgaatg
1321	gaacagcctg	agggatgccc	ccctaagggt	tatgaactta	tgagagcatg	ctggaagtgg

Certificate of Analysis

```

1381 agccctgccg ataggccctc ttttgctgaa acacaccaag cttttgaaac catgttccat
1441 gactccagca tttctgaaga ggtagctgag gagcttggga gagccgcctc ctcgatcatc
1501 gttgttccat acctgccccg gctacctata cttccttcca agactcggac actgaagaaa
1561 caggtggaga acaaggagaa cattgaaggg gcacaagatg ccacagaaaa ttctgcttcc
1621 agtttagcac cagggttcat cagaggtgca caggcctcta gtggatcccc agcactgcct
1681 cgaaagcaaa gagacaagtc acccagcagc ctcttggaag atgccaaaaa gacatgcttc
1741 accagggata ggaagggggg cttcttcagc tccttcatga agaagagaaa tgctcctaca
1801 cccccaaaac gcagcagctc cttccgagaa atggagaatc agccccataa gaaatacgaa
1861 ctcacgggta acttctcatc tgttgcttct ctacagcatg ctgatgggtt ctctttcact
1921 cctgcccagc aagaggcgaa tctggtgcca cccaagtgtc atggggggag ctttgcacag
1981 aggaacctct gtaatgacga cgggtggggg ggtgggggca gtggcactgc tgggggtggg
2041 tgggtctggc tcacaggctt ctttacacca cgcttaatca aaaagacact gggcttacga
2101 gcaggtaaac ccacagccag tgatgacact tccaagcctt ttccaaggtc aaactctaca
2161 tcttccatgt cctcagggct tccagagcag gataggatgg caatgaccct tcccaggaac
2221 tgccagaggt ccaaactcca gctggaaaag acagtgtcca cctcttctca gccagaagag
2281 aatgtggaca gggccaatga catgcttcca aaaaaatcag aggaaagtgc tgctccaagc
2341 agggagagac caaaagccaa gttattgcc agaggagcca cagctcttcc tctcagaaca
2401 ccctctgggg atctagccat tacagagaag gaccctccag ggggtggagt ggctggagtg
2461 gcagctgccc ccaagggtaa agagaagaat ggtggggcac gacttgggat ggctggagt
2521 ccagaggatg gagagcagcc gggctggcct tctccagcca aggctgcccc cgtcctccca
2581 accactcaca accacaaagt gccagtcctt atctcaccca ctctgaaaca cactccagct
2641 gacgtgcagc tcattggcac agactctcag gggaataaat tcaagctctt atctgagcat
2701 caggtcacat cctctggaga caaggaccga ccccgacggg taaaacccaa gtgtgcccc
2761 ccccaccac cagtgtgag actactgcag catccgtcca tctgctcaga ccctacagaa
2821 gagccaactg ccctaactgc aggacagtcc acatcagaaa cacaggaagg aggaaagaag
2881 gcagctctgg gcgcagtgcc catcagtggg aaagtggga ggccagtgat gcctccacct
2941 caagtgcctc tgcccacatc ttccatctcg ccagccaaaa tggccaatgg cacagcaggt
3001 actaaagtgg ctctgagaaa aaccaaacag gccgctgaga aaatctcagc agacaaaatc
3061 agcaaagagg ccctgctgga atgtgctgac ctactgtcca gtgcactcac ggaacctgtg
3121 cccaacagcc agctggtaga cactggacac cagctgcttg actactgctc aggctatgtg
3181 gactgcatcc ctcaaactcg caacaaatct gccttccgag aggctgtgag caaactggaa
3241 ctgagcctgc aggagctaca ggtttcttca gcagctgctg gtgtgcccgg gacaaacct
3301 gtccttaata acttattgtc atgtgtacag gaaatcagtg atgtggtgca gaggtag

```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services.